Clinical Trial Update: Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating switching virologic regimens to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected participants aged 65 and ol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• B/F/TAF FDC (bictegravir/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-12-05